Cargando…
Treatment of Light Chain Deposition Disease Using Bortezomib-Based Regimen Followed by Thalidomide-Based Regimen in a Saudi Male
Light chain deposition disease (LCDD) is a rare illness with, as yet, no clear evidence-based guidelines for its treatment. To the best of our knowledge, LCDD has not been previously reported from Saudi Arabia. We present in this report, a 38-year-old Saudi male who presented with clinical features...
Autores principales: | Adamu, Bappa, Al-Ghamdi, Mushabab, Ahmad, Mustafa, Alsaad, Khaled O. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5204089/ https://www.ncbi.nlm.nih.gov/pubmed/28083151 http://dx.doi.org/10.1155/2016/7485695 |
Ejemplares similares
-
P21 EFFECTIVENESS AND SAFETY OF DELAYED BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE (VTD) REGIMEN
por: Del Fabro, V., et al.
Publicado: (2023) -
Bortezomib-Based Regimens and Plasma Cell Leukemia
por: Bolaman, Ali Zahit
Publicado: (2021) -
Is the Low-Thalidomide Dose MPT Regimen Beneficial?
por: Min, Chang-Ki
Publicado: (2011) -
The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis
por: Lu, Jing, et al.
Publicado: (2015) -
Electroencephalography findings in childhood epilepsy in a Saudi population: Yield, pattern and determinants of abnormality
por: Owolabi, Lukman F, et al.
Publicado: (2020)